The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.
In November 2014, the Pharmacovigilance Centre of Netherlands (Lareb) provided an updated overview of Dutch cases of narcolepsy reported to have a link to Pandemrix.
This is the first published study where an attempt has been made to understand the possible biological mechanisms behind development of narcolepsy following vaccination with Pandemrix™.
This observational cohort study utilizing electronic health care records covering 5.8 million Swedes confirmed an increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents (<
This is the sixth EU Member State reporting an association between the development of narcolepsy and vaccination with the AS03-adjuvanted influenza A H1N1 (2009) pandemic vaccine Pandemrix.
This systematic review and meta-analysis of observational data from an established group of specialists assessed treatment outcomes for all three neuraminidase inhibitors (NAIs); oseltamivir, zanamivir and peramivir given to hospitalised patients with influenza A(H1N1)pdm09 during the 2009 pandemic.
In September 2010 Sweden and Finland noted a number of children had developed narcolepsy seemingly in association with having received the pandemic vaccine used almost exclusively in those countries (Pandemrix)
Antiviral susceptibility is a key area for influenza surveillance as it can affect patient management, prevention of outbreaks and pandemic preparedness.
It is a truism that the number of individual deaths confirmed and reported as due to seasonal or pandemic influenza will represents only a proportion of the actual number of premature deaths that follow as a consequence of the virus infection.